Prognostic Tools in Clinical Pathways and the OCM


Journal of Clinical Pathways spoke with Ray Page, DO, PhD, medical oncologist and hematologist, The Center for Cancer and Blood Disorders (Fort Worth, TX), and Abby Wright, Senior Director of Reimbursement, Biodesix, regarding the importance of prognostic tests—such as Veristrat—in clinical pathways and in aiding achievement of quality measures in the Oncology Care Model.

To read the podcast transcript, click here.

Dr Page recently co-authored a study published in Managed Care, titled "The Role of Proteomic Testing in Improving Prognosis And Care Planning Quality Measures for Lung Cancer," which this podcast references.

There is also a discussion in the podcast regarding a paper Dr Page presented at the American College of Medical Quality Annual Meeting, titled "Precision Medicine: Estimated Clinical and Economic Outcomes of Using a Predictive and Prognostic Biomarker to Avoid IneffectiveTherapies in Advanced Non-Small Cell Lung Cancer."